MedTrace Logo

Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes

NCT01576328 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2020-06-02

No results posted yet for this study

Summary

This study is being conducted to assess the overall safety and tolerability of a single intravenous infusion of three doses of Mesenchymal Precursor Cells versus Placebo in subjects with Type 2 Diabetes inadequately controlled on Metformin.

Conditions

Interventions

DRUG

Mesenchymal Precursor Cells (MPCs)

Single intravenous infusion of MPCs Dose 1

DRUG

Mesenchymal Precursor Cells (MPCs)

Single intravenous infusion of MPCs Dose 2

DRUG

Mesenchymal Precursor Cells (MPCs)

Single intravenous infusion of MPCs Dose 3

Sponsors & Collaborators

  • Mesoblast, Ltd.

    lead INDUSTRY

Principal Investigators

  • K Segal, PhD · Mesoblast, Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2013-10-31
Completion
2015-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01576328 on ClinicalTrials.gov